-
公开(公告)号：US11767322B2
公开(公告)日：2023-09-26
申请号：US17503516
申请日：2021-10-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Guanglin Luo , Jie Chen , Carolyn Diane Dzierba , David B. Frennesson , Junqing Guo , Amy C. Hart , Xirui Hu , Michael C. Mertzman , Matthew Reiser Patton , Jianliang Shi , Steven H. Spergel , Brian Lee Venables , Yong-Jin Wu , Zili Xiao , Michael G. Yang
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,
are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.-
2.发明公开公开(公告)号：US20230183242A1
公开(公告)日：2023-06-15
申请号：US17435819
申请日：2020-03-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： David R. Tortolani , Zheming Ruan , Michael G. Yang , Zili Xiao
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US20210032220A1
公开(公告)日：2021-02-04
申请号：US16982937
申请日：2019-03-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zili Xiao , Michael G. Yang , Chunjian C. Liu , Trevor C. Sherwood , John L. Gilmore , David S. Weinstein
IPC: C07D401/14 , C07D417/14 , C07D513/04 , C07D413/14
Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US20160200728A1
公开(公告)日：2016-07-14
申请号：US14911476
申请日：2014-08-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael G. Yang , Zili Xiao , David S. Weinstein
IPC: C07D487/04
CPC classification number: C07D487/04 , C07D413/06 , C07D413/14
Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-kB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
Abstract translation: 提供新的非甾体化合物，其可用于治疗与调节糖皮质激素受体，AP-1和/或NF-kB活性（包括代谢和炎症和免疫疾病或病症）相关的疾病或障碍，所述糖代谢和炎症和免疫疾病或病症具有式 （I）：其对映异构体，非对映体或互变异构体，或其前药酯或其药学上可接受的盐，其中变量如说明书中所定义。
-
公开(公告)号：US20220119388A1
公开(公告)日：2022-04-21
申请号：US17503516
申请日：2021-10-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Guanglin Luo , Jie Chen , Carolyn Diane Dzierba , David B. Frennesson , Junqing Guo , Amy C. Hart , Xirui Hu , Michael C. Mertzman , Matthew Reiser Patton , Jianliang Shi , Steven H. Spergel , Brian Lee Venables , Yong-Jin Wu , Zili Xiao , Michael G. Yang
IPC: C07D471/04
Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
Patent Agency Ranking
公开(公告)号：US11058696B2
公开(公告)日：2021-07-13
申请号：US16879824
申请日：2020-05-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , T. G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: A61K31/695 , C07F7/08 , A61K31/135 , C07D215/14 , C07D241/04 , C07C323/29 , C07C251/38 , C07C251/42 , C07C251/44 , C07D209/46 , C07D213/38 , C07C275/26 , C07C217/74 , C07C323/25 , C07C235/46 , C07F9/54 , C07F9/572 , C07F9/09 , C07C215/42 , C07C217/52 , C07C217/58 , C07C219/24 , C07C233/41 , C07C233/65 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07D213/32 , C07D213/69 , C07D213/70 , C07D215/12 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F9/117 , C07F9/62 , C07F9/6503 , C07F9/6509 , C07F9/655 , C07F9/6553 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号：US20170304332A1
公开(公告)日：2017-10-26
申请号：US15648250
申请日：2017-07-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , T.G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: A61K31/695 , C07F9/6553 , C07F9/655 , C07F9/6509 , C07F9/6503 , C07F9/62 , C07F9/572 , C07F9/54 , C07F9/117 , C07F9/09 , C07F7/08 , C07D333/16 , C07D319/20 , C07D311/76 , C07D311/58 , C07D309/12 , C07D309/06 , C07D305/08 , C07D277/24 , C07D241/12 , C07D241/04 , C07D239/26 , C07D231/20 , C07D231/12 , C07D217/24 , C07D215/14 , C07D215/12 , C07D213/70 , C07D213/69 , C07D213/38 , C07D213/32 , C07D209/46 , C07C323/29 , C07C323/25 , C07C321/28 , C07C321/22 , C07C321/16 , C07C317/32 , C07C317/28 , C07C275/26 , C07C271/34 , C07C251/54 , C07C251/52 , C07C251/50 , C07C251/44 , C07C251/42 , C07C251/38 , C07C235/46 , C07C233/65 , C07C233/41 , C07C219/24 , C07C217/74 , C07C217/58 , C07C217/52 , C07C215/42 , A61K31/661 , A61K31/505 , A61K31/4965 , A61K31/47 , A61K31/4409 , A61K31/4406 , A61K31/4402 , A61K31/44 , A61K31/426 , A61K31/4174 , A61K31/415 , A61K31/381 , A61K31/352 , A61K31/351 , A61K31/337 , A61K31/27 , A61K31/24 , A61K31/222 , A61K31/17 , A61K31/166 , A61K31/165 , A61K31/15 , A61K31/137 , A61K31/135 , C07C2601/04 , C07C2601/08 , C07C2603/74 , C07C2602/10 , C07C2601/02
CPC classification number: A61K31/695 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661 , C07B2200/05 , C07C215/42 , C07C217/52 , C07C217/58 , C07C217/74 , C07C219/24 , C07C233/41 , C07C233/65 , C07C235/46 , C07C251/38 , C07C251/42 , C07C251/44 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C275/26 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07C323/25 , C07C323/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/10 , C07C2603/74 , C07D209/46 , C07D213/32 , C07D213/38 , C07D213/69 , C07D213/70 , C07D215/12 , C07D215/14 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/04 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/081 , C07F9/091 , C07F9/117 , C07F9/5442 , C07F9/5728 , C07F9/62 , C07F9/65031 , C07F9/650952 , C07F9/65522 , C07F9/655345
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号：US09770459B2
公开(公告)日：2017-09-26
申请号：US15337843
申请日：2016-10-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. Dyckman , T.G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: C07D217/00 , A61K31/695 , C07C215/42 , C07C217/52 , C07C217/58 , C07C219/24 , C07C233/41 , C07C233/65 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07D213/32 , C07D213/69 , C07D213/70 , C07D215/12 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/08 , C07F9/117 , C07F9/62 , C07F9/6503 , C07F9/6509 , C07F9/655 , C07F9/6553 , A61K31/135 , C07D215/14 , C07D241/04 , C07C323/29 , C07C251/38 , C07C251/42 , C07C251/44 , C07D209/46 , C07D213/38 , C07C275/26 , C07C217/74 , C07C323/25 , C07C235/46 , C07F9/54 , C07F9/572 , C07F9/09 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661
CPC classification number: A61K31/695 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661 , C07B2200/05 , C07C215/42 , C07C217/52 , C07C217/58 , C07C217/74 , C07C219/24 , C07C233/41 , C07C233/65 , C07C235/46 , C07C251/38 , C07C251/42 , C07C251/44 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C275/26 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07C323/25 , C07C323/29 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/10 , C07C2603/74 , C07D209/46 , C07D213/32 , C07D213/38 , C07D213/69 , C07D213/70 , C07D215/12 , C07D215/14 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/04 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F7/081 , C07F9/091 , C07F9/117 , C07F9/5442 , C07F9/5728 , C07F9/62 , C07F9/65031 , C07F9/650952 , C07F9/65522 , C07F9/655345
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
公开(公告)号：US11787779B2
公开(公告)日：2023-10-17
申请号：US17242428
申请日：2021-04-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Chunjian Liu , Michael G. Yang , Zili Xiao , Ling Chen , Ryan M. Moslin , John S. Tokarski , David S. Weinstein , Stephen T. Wrobleski
IPC: C07D401/12 , C07D401/14 , C07D413/14 , C07D471/04 , C07D405/14 , C07F9/6558 , C07D417/14 , A61P37/00 , A61P29/00 , A61K31/501 , C07D487/04
CPC classification number: C07D401/14 , A61K31/501 , A61P29/00 , A61P37/00 , C07D401/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07F9/65583
Abstract: Compounds having the following formula I:
or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.-
公开(公告)号：US20220331346A1
公开(公告)日：2022-10-20
申请号：US17307138
申请日：2021-05-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Alaric J. DYCKMAN , T.G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux
IPC: A61K31/695 , C07F7/08 , A61K31/135 , C07D215/14 , C07D241/04 , C07C323/29 , C07C251/38 , C07C251/42 , C07C251/44 , C07D209/46 , C07D213/38 , C07C275/26 , C07C217/74 , C07C323/25 , C07C235/46 , C07F9/54 , C07F9/572 , C07F9/09 , C07C215/42 , C07C217/52 , C07C217/58 , C07C219/24 , C07C233/41 , C07C233/65 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07D213/32 , C07D213/69 , C07D213/70 , C07D215/12 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F9/117 , C07F9/62 , C07F9/6503 , C07F9/6509 , C07F9/655 , C07F9/6553 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.036 seconds)
